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Acute myocardial infarction (MI) is a severe ischemic disease responsible for heart 
failure and sudden death. Here, we show that following acute MI in mice, mature B 
lymphocytes selectively produce Ccl7 and induce Ly6Chi monocyte mobilization and 
recruitment, leading to enhanced tissue injury and deterioration of myocardial 
function. Genetic (Baff-r deficiency) or antibody-mediated (CD20- or Baff-specific 
antibody) depletion of mature B lymphocytes impedes Ccl7 production and 
monocyte mobilization, limits myocardial injury and improves heart function. These 
effects are recapitulated in mice with B cell selective Ccl7 deficiency. We also show 
that elevated circulating levels of Ccl7 and Baff in patients with acute MI predict 
increased risk of death or recurrent MI at follow-up. The work unravels a 
previously unsuspected interaction between mature B lymphocytes and monocytes 
following acute ischemia, and identifies novel therapeutic targets for this 
devastating condition. 
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Acute thrombotic obstruction of the blood flow in coronary arteries precipitates 
myocardial infarction (MI) with deleterious consequences on heart function 1-4. The 
mainstay of treatment involves rapid restoration of a patent coronary artery either 
mechanically or through thrombolytic and anti-platelet therapies, and administration of 
agents that reduce oxygen consumption and unload the heart muscle 1,5. Still, the clinical 
and social burden of ischemic heart disease is unacceptably high and the efficacy of 
additional anti-thrombotic therapies is often mitigated by the increased risk of 
hemorrhagic events. Thus, efforts are being directed towards targeting other 
pathophysiological pathways, particularly those involved in post-ischemic cardiac 
remodeling 4,6. 
 The immune system becomes activated in response to myocardial damage 7. Shortly after 
ischemia, the damaged tissue exposes ligands (i.e., non-myosin heavy chain type IIA and 
C) that are recognized by components of the innate immune system, which leads to its 
activation 8-12. C-reactive protein (CRP), a short pentraxin acute-phase protein, also binds 
to damaged tissue and activates complement, leading to aggravation of tissue injury in the 
setting of acute MI 13. In contrast, long pentraxin 3, a molecule that limits complement 
activation plays a cardioprotective role in this setting 14. The acute inflammatory response 
also leads to the mobilization and recruitment of innate immune cells. Few hours after the 
ischemic insult, neutrophils are actively recruited into the ischemic tissue and contribute 
to tissue inflammation and cardiovascular injury through the production of inflammatory 
mediators, reactive oxygen species and various proteases 15,16. The wave of neutrophil 
infiltration is followed by the mobilization and recruitment of monocytes. Recent studies 
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have shed new light on the mechanisms of monocytes recruitment and life cycle in the 
setting of acute MI. The studies suggested differential pathogenic or protective roles for 
Ly6Chi and Ly6Clo monocytes, respectively, in cardiac remodeling and preservation of 
heart function 17,18. Despite this increasing knowledge, the utility of targeting the immune 
response in this setting is still uncertain as revealed by the lack of efficacy of complement 
inhibition in patients with acute MI 19-22. Thus, a better characterization of the 
determinants of the immune response following ischemic injury and the mechanisms by 
which they contribute to tissue damage is required in order to fill the existing gap of 
knowledge that limits clinical translation, and design efficient therapeutic strategies for 
future use in humans. 
Here, we addressed the role of mature B lymphocytes, a subset of immune cells that 
orchestrates a variety of adaptive immune responses relevant to human diseases 23, but 
that has relatively been neglected in the setting of ischemic injury. We show that 
following acute MI in mice, mature B lymphocytes are activated to produce Ccl7, a 
chemokine that induces monocyte mobilization from the bone marrow, leading to 




Mature B cells are recruited to the ischemic tissue after MI 
To identify the inflammatory cell repertoire within the injured myocardium, we induced 
acute MI in C57BL/6J mice by permanent coronary artery ligation and analyzed cell 
suspensions of digested infarcts at different time points by flow cytometry. We found that 
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neutrophils (CD11b+ Ly6Ghi 7/4hi cells) peaked as early as day 1 after MI 
(Supplementary Fig. 1a), followed by successive waves of 7/4hi (Ly6Chi) and 7/4lo 
(Ly6Clo) monocytes (CD11bhi Ly6G⎯) (Supplementary Fig. 1b), and by accumulation 
of dendritic cells, macrophages and Natural Killer cells (Supplementary Fig. 1c and 
1d). We also found that CD3+ T lymphocytes accumulated in the injured myocardium 
within 1 day after MI and dropped thereafter (Supplementary Fig. 1e). The results are in 
agreement with previous studies 17. Intriguingly, the duration and the intensity of B 
lymphocyte infiltration into the ischemic cardiac tissue remain largely undefined. We 
found that B lymphocytes, defined as B220+ IgM+ cells, accumulated in the infarct area, 
peaked on day 5 after MI and waned thereafter to levels comparable to those in sham-
operated mice (Supplementary Fig. 2a). Immunohistological and additional flow 
cytometry analyses confirmed the increased accumulation of B220-positive and 
CD19+IgD+IgMlow B lymphocytes in the border infarct area after MI compared to sham-
operated animals (Supplementary Fig. 2b and 2c). Thus, myocardial infarction triggers 
the infiltration of circulating mature B lymphocytes into cardiac tissue, suggesting a 
potential role of B cell-mediated immune response in this setting. 
 
B cell depletion prevents adverse remodeling and improves cardiac function  
To directly assess the role of mature B lymphocytes in cardiac remodeling after MI, we 
depleted B lymphocytes using a CD20-specific monoclonal antibody (CD20 mAb) 24,25. 
As expected, we found that CD20 mAb treatment led to sustained and profound reduction 
of the number of mature B lymphocytes in cardiac tissue (Supplementary Fig. 3a), the 
peripheral blood (Fig. 1a) and the spleen (Supplementary Fig. 3b). Both follicular (FO) 
Zouggari et al., NMED-A59989B-revision 
 7
and marginal zone (MZ) B cells were depleted (Supplementary Fig. 3c) whereas B1 
cells were preserved during the duration of the experiment (data not shown)26. We next 
assessed cardiac function by echocardiography 14 days after MI. Of interest, CD20 mAb-
induced B cell depletion led to a reduction in end-systolic left ventricular (LV) dimension 
(P = 0.016), a significant improvement of LV shortening fraction (P = 0.021) and an 
increase in LV myocardial contractility (P = 0.025) compared to control animals (Fig. 
1b). This was associated with a reduction of infarct size (P = 0.024) and interstitial 
fibrosis as assessed by collagen content (P = 0.016) (Fig. 1c). In addition, B cell 
depletion reduced the number of apoptotic cells within the injured myocardium, as shown 
by TUNEL staining (P = 0.005) but had no effect on neovascularization (Supplementary 
Fig. 4). Overall, these results show that systemic B cell depletion significantly reduces 
post-ischemic injury, prevents adverse ventricular remodeling and improves cardiac 
function after acute MI.  
 
B cell depletion reduces both systemic and local pro-inflammatory responses  
We next assessed the potential mechanisms involved in B cell-mediated effects on 
cardiac remodeling and function. Previous studies reported a pathogenic role for natural 
IgM antibodies in the first 24 hours following ischemia-reperfusion injury 11,27. We 
therefore assessed changes in antibody production after CD20 mAb treatment. Mature B 
cell depletion did not alter IgM or IgG levels in the first three days after MI, making 
unlikely the hypothesis of an antibody-mediated effect (Supplementary Fig. 5). The 
moderate decrease of IgM levels at day 14 after MI in CD20 mAb-treated animals 
(Supplementary Fig. 5) might be secondary to the reduction of myocardial necrosis. 
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We next assessed changes in the inflammatory response. Treatment with CD20 mAb 
resulted in a profound reduction of both systemic and local pro-inflammatory cytokines 
measured at day 14 after MI. Hence, IL-1β (P = 0.04), TNF-α (P = 0.004) and IL-18 (P = 
0.041) mRNA levels were significantly lower in infarct hearts of B cell depleted-mice 
compared to the control group (Fig. 1d). In contrast, expression of anti-inflammatory 
mediators, IL-10 and TGF-β, tended to be unaffected in the B cell-depleted animals (Fig. 
1d). Similar results were found in spleens and lymph nodes of B cell-depleted mice 
(Supplementary Fig. 6a and 6b), suggesting a limited inflammatory response. 
 
B cell depletion impairs monocyte mobilization and recruitment after acute MI 
We then addressed the mechanisms that could account for the reduced inflammatory 
response and the improvement in ventricular remodeling. A striking observation was that 
B cell-depleted mice constantly showed altered monocyte compartmentalization as 
revealed by enhanced accumulation of 7/4hi monocytes in the bone marrow (P = 0.01 vs 
controls) (Fig. 2a) and the spleen (p=0.02 vs controls) (Supplementary Fig. 7), 
associated with a significant decrease of their circulating blood count (P = 0.015 vs PBS) 
(Fig. 2b), suggesting impaired monocyte mobilization. 
We also addressed the effect of CD20-mediated B cell depletion on monocyte 
recruitment from the circulating blood into the ischemic heart. Mice underwent coronary 
artery ligation and were treated (1h after ligation) with either PBS or CD20 mAb. Four 
hours after MI, the 2 groups of mice received an intravenous infusion of CD45.1+ 
mononuclear cells (15 x 106). We then quantified the number of recruited CD45.1+ 
CD11b+ Ly6G– Ly6C+ cells in the myocardium 3 days after monocyte transfer. As shown 
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in Fig. 2c, CD20-mediated B cell depletion led to substantial reduction in monocyte 
recruitment into the ischemic myocardium. We also found a non-significant trend 
towards reduced accumulation of 7/4hi monocytes (Supplementary Fig. 8a) and a 
substantial reduction of macrophage accumulation within the ischemic heart 3 and 5 days 
after CD20 mAb treatment, respectively (Fig. 2d). Other cell subsets were not altered 
(Supplementary Fig. 8b and 8c). 
 
B lymphocytes produce Ccl7 and trigger monocyte migration  
Since Ccr2-mediated signals are required for monocyte mobilization from the bone 
marrow 17,28 and recruitment into injured tissues, we examined potential changes in the 
production of Ccl2 and Ccl7, the 2 major Ccr2 ligands. We found that acute MI led to a 
significant increase of both Ccl2 and Ccl7 mRNA and protein levels, in blood and cardiac 
tissue (Supplementary Fig. 9). Intriguingly, B cell depletion was associated with a 
significant and selective impairment of Ccl7 levels (P = 0.03) compared to the control 
group, while Ccl2 (and Ccl12) levels were not significantly affected by B cell depletion 
(Fig. 3a and Supplementary Fig. 9). 
These results suggested that B lymphocytes might produce Ccl7 and induce Ccl7-
dependent monocyte mobilization. To address this hypothesis, we first evaluated Ccl7 
expression by splenic B cells using flow cytometry and RT-qPCR. We found that CD19+ 
B lymphocytes, which are markedly depleted after CD20 mAb treatment, express Ccl7, 
with higher expression after myocardial infarction (Supplementary Fig. 10). 
Interestingly, spleen B cells of Myd88–/–Trif–/– mice produced substantially less Ccl7 than 
B cells of WT animals after MI (Supplementary Fig. 10). We also assessed Ccl7 
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secretion by cultured B lymphocytes. Whereas Ccl2 and Ccl12 remained undetectable in 
supernatants of B lymphocytes (data not shown), these cells produced significant amount 
of Ccl7, which was further increased after their activation with anti-CD40 and anti-IgM 
antibodies (data not shown) or with TLR agonists, particularly CpG (Fig. 3b and 
Supplementary Fig. 10). We also found that activated cultured B lymphocytes strongly 
enhanced 7/4hi monocytes transmigration in vitro compared to non-stimulated B 
lymphocytes (P < 0.0001) (Fig. 3c). Interestingly, neutralizing anti-Ccl7 antibody 
abrogated B cell-induced migration of cultured 7/4hi monocytes (P = 0.0003), while Ccl2 
neutralization had no effects (Fig. 3c). 
  
Ccl7-deficient B cells fail to affect cardiac remodeling and function after acute MI 
These findings prompted us to investigate the direct role of B cell-derived Ccl7 in post-
ischemic cardiac remodeling. First, we unraveled a key role of Ccl7 in this setting using 
Ccl7-deficient mice. We found that following acute MI, Ccl7 deficiency was associated 
with a reduction of 7/4hi monocyte mobilization from bone marrow (P = 0.013 vs WT) to 
the blood (P = 0.04 vs WT), and improvement of cardiac function (Supplementary Fig. 
11). To further substantiate the role of B cell-derived Ccl7 in this setting, we injected 
Rag1⎯/⎯ mice either with wild-type splenocytes, B cell-depleted splenocytes, or B cell-
depleted splenocytes re-supplemented with wild-type or Ccl7⎯/⎯ B lymphocytes. The 
purity of the B lymphocytes is shown in Supplementary Fig. 12. We first verified that 
re-supplementation with wild-type or Ccl7⎯/⎯ B lymphocytes significantly increased B 
cell numbers in spleens of Rag1⎯/⎯ mice compared to mice injected with B cell-depleted 
splenocytes only (Supplementary Fig. 12). We then evaluated circulating Ccl7 levels 
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and found that re-supplementation with wild-type B lymphocytes was associated with an 
increase of Ccl7 levels compared to mice receiving B cell-depleted splenocytes only 
(968.5 ± 46.06 pg ml−1 and 201.1 ± 28.31 pg ml−1, respectively, P < 0.0001).  In contrast, 
re-supplementation of B cell-depleted splenocytes with B lymphocytes isolated from 
Ccl7⎯/⎯ mice failed to increase Ccl7 levels (152.6 ± 39.9 pg ml−1, P < 0.0001 vs wild-
type B lymphocytes).  Interestingly, we also found that re-supplementation with wild-
type B lymphocytes was associated with an increase of 7/4hi monocyte numbers in the 
blood and within the injured myocardium compared to the group receiving B cell-
depleted splenocytes only (Fig. 3d), a phenotype that was abrogated in mice re-
supplemented with Ccl7⎯/⎯ B lymphocytes (Fig. 3d). Thus, B cell-derived Ccl7 triggers 
selective mobilization and tissue recruitment of 7/4hi monocytes after acute MI. 
We then examined the consequences of Ccl7 deficiency in B lymphocytes on post-
ischemic cardiac remodeling. We found that transfer of B cell-depleted splenocytes into 
Rag1⎯/⎯ mice reduced end-systolic LV chamber dimension (P = 0.04) and improved left 
ventricular shortening fraction (P = 0.008) after MI compared to the transfer of non-
depleted splenocytes (Fig. 4a). This effect was abrogated after re-supplementation of B 
cell-depleted splenocytes with B lymphocytes isolated from wild-type mice (P = 0.0007 
and P = 0.02 respectively) but was not altered after re-supplementation with Ccl7⎯/⎯ B 
lymphocytes (Fig. 4a). B cell depletion also reduced infarct size (p=0.04; Fig. 4b) and 
collagen content (Fig. 4c), which was antagonized by re-supplementation with wild-type 
but not with Ccl7⎯/⎯ B lymphocytes (Fig. 4b and 4c). Circulating IgM and IgG levels 
were similar in mice re-supplemented with wild-type versus Ccl7⎯/⎯ B lymphocytes 
(Supplementary Fig. 12), making unlikely a contribution of humoral immunity to the 
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cardioprotective effect, although we did not measure specific antibody titers.  
We also generated a B cell-restricted Ccl7 deficient mouse model by reconstituting 
lethally-irradiated wild-type animals with a mixture of bone marrow from μMT and 
Ccl7⎯/⎯ mice (see Methods online). The control group received a mixture of μMT and 
Ccl7+/+ bone marrow. Again, we found that restricted Ccl7 deficiency in B lymphocytes 
led to reduction of circulating Ccl7 levels (Fig. 4d) and improved heart function after 
acute MI (Fig. 4e). 
 
Blockade of Baff signaling impairs monocyte mobilization and improves heart 
function  
Baff signaling through Baff receptor (Baff-r) is required for the maintenance of mature 
B2 cells and Baff-r⎯/⎯ mice are characterized by a profound reduction of follicular (FO) 
and marginal zone (MZ) B lymphocytes but preservation of B1 cells 29 (and 
Supplementary Fig. 13). We therefore addressed the impact of Baff-r deficiency on the 
pathophysiology of post-ischemic myocardial injury. Interestingly, we found that Baff-
r⎯/⎯ mice showed a significant increase in the accumulation of Ly6Chi monocytes in the 
bone marrow but displayed lower levels of these monocytes in the circulating blood 
compared with control littermates (Fig. 5a and Supplementary Fig. 13), clearly 
suggesting impaired monocytes mobilization. This was associated with reduced levels of 
circulating Ccl7 in Baff-r⎯/⎯ mice (Fig. 5b). Importantly, Baff-r deficiency improved 
heart function after MI as shown by the significant increase of shortening fraction in Baff-
r⎯/⎯ mice compared with Baff-r+/⎯ littermates (Fig. 5c) despite no change in infract size 
(Supplementary Fig. 13). To further substantiate the role of Baff in this context, we 
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treated a group of wild-type mice with anti-Baff monoclonal antibody (see Methods 
online). We found that Baff neutralization led to significant depletion of circulating B 
lymphocytes (Fig. 5d), which was associated with impaired Ly6Chi monocyte 
mobilization (Fig. 5e and Supplementary Fig. 13) and improved cardiac function (Fig. 
5f).  
 
Circulating levels of CCL7 and BAFF predict adverse cardiovascular outcome 
Finally, we addressed the relevance of these findings to the human disease by assessing 
the relationship between circulating CCL7 or BAFF levels and clinical outcomes in a 
cohort of 1,000 patients admitted for acute MI. Patients’ characteristics are given in 
Supplementary Table 1 and Supplementary Table 2. Interestingly, we found that 
patients with detectable circulating levels of CCL7 at their admission for acute MI were 
at substantially increased risk of death and recurrent myocardial infarction after two years 
of follow-up compared to patients with no detectable CCL7 levels even after adjustment 
for several multivariable risk factors (see Methods) (hazard ratio, HR=1.54, 95% CI = 
1.07-2.43, P = 0.02) (Fig. 6a). Similarly, the risk of death and recurrent MI was 
associated with increasing tertiles of circulating BAFF at admission. The HR of death and 
recurrent MI in the second and third tertiles of BAFF were 1.65 (1.05-2.58) and 3.14 
(2.09-4.73) compared with the lowest tertile (P < 0.0001). The association remained 
significant in a fully adjusted model (Fig. 6b). 
  
Zouggari et al., NMED-A59989B-revision 
 14
DISCUSSION 
B lymphocytes play critical non-redundant roles mediating both innate and adaptive 
immune responses through antibody-dependent or independent mechanisms. More recent 
studies identified novel roles for B lymphocytes in the early innate immune response 
during acute infection 30,31 where B lymphocytes were required to mount an efficient and 
protective inflammatory response. However, the contribution of B lymphocytes to the 
inflammatory response secondary to other forms of acute injury, particularly post-
ischemic injury is still poorly defined. Our results unravel a critical role for B cell-
dependent Ccl7 production in the pathogenic response to acute ischemic injury. The 
precise B cell subset involved in this setting remains to be examined in more detail. 
However, our results indicate that it depends in part on Baff-r signaling. 
From previous studies, B cell responses appeared to be redundant in post-ischemic stroke 
injury as B cell-deficient (μMT) mice showed no difference in infarct size or neurological 
deficit when compared with wild type mice 32. Other studies addressed the role of B 
lymphocytes in response to ischemia/reperfusion injury in the kidney. However, the use 
of B cell-deficient μMT mice by various groups in this setting has led to very divergent 
results, with studies showing either protection 33,34 or aggravation 12 of 
ischemia/reperfusion injury in mice lacking B cells. The use of μMT mice should be 
interpreted with caution given the wide range of associated immune abnormalities and the 
fact that both innate and adaptive B lymphocytes, with potentially divergent functions, 
are absent in this strain. A previous study showed that intra-myocardial injection of bone 
marrow-derived B cells after acute MI in rats improved the recovery of myocardial 
function 35. However, there are major differences with the present work. In the previous 
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study, bone marrow-derived B lymphocytes were mostly immature B cells that are 
resistant to CD20 mAb-mediated B cell depletion. In addition, the mechanisms of 
protection afforded by the injection of exogenous immature B lymphocytes remained 
obscure and the investigators did not assess the role of endogenous B lymphocytes in this 
setting. 
We and others have shown that Baff-r deficiency or CD20 mAb-induced B cell depletion 
holds promise in the context of cardiovascular disease and reduces the development of 
atherosclerotic lesions in several experimental models 25,36-38. Our present data clearly 
show that depletion of mature B lymphocytes after CD20 mAb injection at the acute 
phase of myocardial infarction leads to significant improvement in both post-ischemic 
ventricular remodeling and myocardial function. Similar results were obtained using 
Baff-r⎯/⎯ mice or a neutralizing Baff-specific antibody, although effects on infarct size 
differed between CD20 mAb treatment and blockade of Baff signaling. It should be noted 
that Baff receptor is also expressed on non B cells and that B cell depletion was delayed 
in mice treated with Baff-specific, requiring a second antibody injection at day 1 to 
obtain a substantial depletion whereas B cells already disappeared from the blood in 
CD20 mAb-treated mice a few hours after a single injection (Fig. 1 and data not shown).  
Future work should address the mechanisms responsible for B cell activation after acute 
ischemic injury and the pathways that drive B cell-dependent Ccl7 production. For 
example, several endogenous toll-like receptor ligands may accumulate after necrosis and 
could lead to B cell activation. In this regard, it is interesting to note that spleen B cells of 
Myd88–/–/Trif–/– mice produce substantially less Ccl7 than B cells of WT animals. 
Whether this is related to selective Myd88/Trif signaling in B cells and whether it can 
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directly impact systemic Ccl7 levels remains to be determined. Moreover, it will be 
important to address in more detail the contribution of the various B cell and monocyte 
subsets to post-ischemic injury. The substantial reduction of Ly6Clo monocytes in blood 
after B cell depletion or blockade of Baff signaling might be in part related to reduced 
Ccl7 signaling 28 (Supplementary Fig. 11) or may suggest the involvement of additional 
chemokine pathways, like Cx3cr1. However, we found no difference in Cx3cl1 
production between CD20-depleted and control animals (data not shown). Finally, pilot 
data suggest that Cxcl13 may be induced after MI (data not shown) and might play a role 
in B cell recruitment into the ischemic heart. However, the selective role of B cells that 
accumulate in the heart after MI is still poorly understood.  
In summary, these studies delineate an important contributory role for systemic B cells 
during the immune responses that lead to tissue damage following acute MI. Neutrophils, 
monocyte subsets, NK cells and T cells enter the site of injury. The release of 
inflammatory mediators and tissue antigens appears to result in the rapid activation of B 
cells systemically leading to B cell production of Ccl7, in part through a MyD88-
dependent pathway. B cells are also secondary recruited to the ischemic heart as a 
component of the inflammatory response. B cell-derived Ccl7 probably synergizes with 
Ccl7 produced from other cellular sources to increase serum chemokine levels, which 
facilitates the mobilization of monocytes from the bone marrow and results in enhanced 
monocyte entry into sites of tissue damage. B cell depletion reduces Ccl7 production and 
the magnitude of 7/4hi monocyte recruitment and macrophage accumulation into post-
ischemic tissues. Because B cells are well known to promote pro-inflammatory innate 
and adaptive immune responses 39, their systemic depletion is likely to further reduce T 
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cell-, macrophage- and neutrophil-induced tissue damage by reducing the systemic 
amplification of the inflammatory response following a MI. As a consequence, B cell 
depletion is shown here to have a profound impact on post-ischemic injury. It 
substantially limits myocardial inflammation, reduces infarct size and improves 
myocardial function. The positive associations of BAFF or CCL7 circulating levels with 
adverse outcomes in patients with acute MI strongly support a clinical relevance to the 
human disease. 
Of note, the depleting CD20 mAb and anti-Baff mAb were administered 1 hour after the 
induction of myocardial infarction, which mimics clinical settings where a therapeutic 
agent is administered in the first hours after the onset of clinical symptoms/signs of acute 
ischemic injury. Thus, we believe that the present study sets the stage for the testing of 
available humanized B cell-depleting antibodies at the acute phase of myocardial 
infarction with the aim to limit myocardial necrosis, inflammation and improve the 
recovery of heart function. In addition, we anticipate that therapies targeting pathways 
that control mature B lymphocytes, i.e., Baff or Ccl7 pathways, should be of interest in 
the setting of acute ischemic injury.
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FIGURE LEGENDS 
Figure 1. The B cell depleting CD20 antibody reduces infarct size, improves heart 
function and limits myocardial inflammation. (a) Representative examples and 
quantitative analysis of B220hi IgM+ B cells staining in the blood of C57BL/6J mice 
treated with or without the CD20 antibody (anti-CD20) (n = 12 to 15 mice per group); 
*** P < 0.001. (b) Echocardiography analysis after anti-CD20 therapy. We measured LV 
shortening fraction (SF), LV internal diameter at end systole (LVIDs) and LV posterior 
wall thickness at end systole (LVPWs); * P < 0.05. (c) Representative photomicrographs 
and quantitative analysis of infarct size and myocardial fibrosis evaluation evaluated by 
Masson trichrome and Sirius Red stainings, respectively, in the 2 groups of mice. Data 
are representative of 10-14 mice per group in three independent experiments. Bars, upper 
panels, 1mm; lower panels,100 μm. (d) Representative histograms of mRNA levels of the 
pro-inflammatory cytokines IL-1β, TNF-α, IL-18 and the anti-inflammatory cytokines 
IL-10 and TGF-β, within the injured myocardium on day 14 after MI (n = 8-12 per 
group). Mean values ± SEM are represented. * P < 0.05; ** P < 0.01 vs PBS. 
 
Figure 2. B lymphocyte depletion impairs monocyte mobilization, recruitment and 
macrophage accumulation in the injured myocardium. Representative examples of 
7/4hi and 7/4lo monocyte stainings as well as quantification of their numbers in bone 
marrow (a) and blood (b) of B cell-depleted mice compared to controls on day 3 after MI 
(n = 8-15 per group). Mean values ± SEM are represented. * P < 0.05 vs PBS. (c) 
Quantitative analysis of CD45.1+ CD11b+ Ly6G– Ly6C+ cells in the cardiac tissue of 
anti-CD20 treated animals compared to controls on day 3 after MI (n = 5 per group). (d) 
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Quantitative analysis of F4/80+ and CD68+ macrophages within the myocardium on day 5 
post-MI (n = 5 per group). Mean values ± SEM are represented. * P < 0.05 vs PBS. 
 
Figure 3. B lymphocyte depletion selectively reduces Ccl7 levels after acute MI and 
trigger Ccl7-dependent monocyte transmigration in vitro and in vivo. (a) Ccl2 and 
Ccl7 protein levels in blood after CD20 mAb treatment, 1 and 3 days after MI (n = 5-8 
per group). (b) Bar graphs show Ccl7 release in the supernatant of non-stimulated or 
CpG-stimulated cultured B cells. Control ODN did not induce Ccl7 production (data not 
shown). (c) Representative photomicrographs and histograms of the transmigration of 
cultured monocytes in the presence of non-stimulated or activated (IgM and CD40) B 
cells with or without neutralizing anti-Ccl2 or anti-Ccl7 antibodies. Data are 
representative of four independent experiments, each condition was performed in 
triplicate. Bars, 300 μm. Mean values ± SEM are represented. * P < 0.05; *** P < 0.001 
vs control. No cells could be counted when B cells were cultured in the absence of 
monocytes in the upper compartment, indicating no B cell contamination (d) 
Quantification of 7/4hi monocytes in blood (left) and in the infarcted myocardium (right) 
of Rag1⎯/⎯ mice injected with either wild-type splenocytes, B cell-depleted splenocytes, 
or B cell-depleted splenocytes re-supplemented with wild-type or Ccl7⎯/⎯ B cells, 3 days 
after MI. Data are representative of 10 to 12 mice per group in two independent 
experiments. Mean values ± SEM are shown. * P < 0.05 vs WT splenocytes ; ## P < 0.01 
vs anti-CD20 splenocytes; $ P < 0.05 vs anti-CD20 splenocytes with WT B cells.  
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Figure 4. B lymphocytes trigger adverse ventricular remodeling and alter heart 
function through the production of Ccl7. (a) Echocardiography analysis after 14 days 
of MI and assessment of LV shortening fraction (SF), LV internal diameter at end systole 
(LVIDs) and LV posterior wall thickness (LVPWs) of Rag1⎯/⎯ mice injected with either 
wild-type splenocytes, B cell-depleted splenocytes, or B cell-depleted splenocytes re-
supplemented with wild-type or Ccl7⎯/⎯ B cells. (b, c) Representative photomicrographs 
and quantitative analysis of infarct size (b), fibrosis and collagen content (c) in the 4 
groups of mice. Results are pooled from three independent experiments with 10 to 25 
mice per group. Mean values ± SEM are shown. Bars, 1 mm in (b) and 100 μm in (c). * 
P < 0.05 and *** P < 0.001 vs WT splenocytes ; # P < 0.05 and ### P < 0.001 vs α-CD20 
splenocytes; $ P < 0.05 and $$$ P < 0.001 vs anti-CD20 splenocytes with WT B cells. (d, 
e) Restricted Ccl7 deficiency in B cells improved heart function after acute MI. (d) 
Quantitative analysis of circulating Ccl7 protein levels at day 14 post-MI in animals 
repopulated with a mixture of μMT and Ccl7⎯/⎯ bone marrow compared to the control 
group receiving a mixture of μMT and Ccl7+/+ bone marrow. (e) Quantitative analysis of 
the shortening fraction (%) at day 14 post-MI in the 2 groups of mice (n = 9 to 13 mice 
per group). Mean values ± SEM are shown. * P < 0.05.   
 
Figure 5. Blockade of Baff signaling impairs monocyte mobilization and improves 
heart function after acute MI. (a) Quantification of the number of 7/4hi monocytes in 
the bone marrow (left) and in the blood (right) of Baff-r⎯/⎯ mice compared to controls on 
day 3 after MI. (b) Ccl7 protein levels in the plasma of Baff-r⎯/⎯ mice compared to 
controls at day 3 post-MI. (c) Quantitative analysis of the shortening fraction (%) of Baff-
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r⎯/⎯ mice compared to Baff-r+/+ and Baff-r+/⎯ mice at day 14 post-MI. Data are 
representative of 8 to 11 mice per group. Mean values ± SEM are shown. * P < 0.05 and 
** P < 0.01.  (d, e) Quantification of the number of B220+ IgM+ B cells (d) and 7/4hi 
monocytes (e) in blood of anti-Baff treated mice compared to PBS injected animals. (f) 
Quantitative analysis of the shortening fraction (%) of anti-Baff treated mice compared to 
PBS at day 14 post-MI (n = 12 to 15 mice per group). * P < 0.05, ** P < 0.01, *** P < 
0.001. 
 
Figure 6. Circulating levels of CCL7 and BAFF at the acute phase of MI are 
associated with cardiovascular outcomes. (a) The probability of outcome events (death 
or recurrent MI) as a function of baseline circulating CCL7 (a) or BAFF (b) level in 
patients with acute MI. Detectable CCL7 levels or high levels of BAFF at the admission 
for acute MI were independently predictive of death and recurrent MI after two years of 
follow-up after multiple adjustments (see Methods). HR= Hazard ratio. 
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Myocardial infarction. All mice were on full C57Bl/6J background. C57BL/6 (Janvier, 
France), Ccl7⎯/⎯ 28, Baff-r⎯/⎯ , Rag1⎯/⎯, CD45.1 mice (The Jackson Laboratory) and 
Myd88⎯/⎯ Trif⎯/⎯ mice (provided by Ryffel B 40) were 8 weeks old. Myocardial 
infarction was induced by left coronary ligation 41. Mice were anesthetized using 
ketamine (870 mg kg−1) and xylazine (140 mg kg−1) via intraperitoneal injection (i.p.), 
then intubated and ventilated with air using a small animal respirator. The chest wall was 
shaved and a thoracotomy was performed in the fourth left intercostal space. The left 
ventricle was visualized, the pericardial sac was then removed and the left anterior 
descending artery was permanently ligated using a 7/0 monofilament suture (Péters 
surgical, France) at the site of its emergence from under the left atrium. Significant color 
changes at the ischemic area were considered indicative of successful coronary occlusion. 
The thoracotomy was closed with 6/0 monofilament sutures. The same procedure was 
performed for sham-operated control animals except that the ligature was left untied. The 
endotracheal tube was removed once spontaneous respiration resumed, and animals were 
placed on a warm pad maintained at 37 °C until the mice were completely awake. One 
hour after myocardial infarction induction, mice were treated i.p. with a mouse 
monoclonal CD20 antibody (200 μg/mouse) 24,25, with an anti-Baff antibody (clone 10F4, 
100 μg/mouse, repeated at day1 after MI) 42  or with PBS. In leukocytes recruitment 
experiments, CD20 mAb-treated mice or untreated group received both 15 x 106 CD45.1+ 
bone marrow mononuclear-derived cells 4 hours after MI. In other sets of experiments, 7 
days before myocardial infarction induction, Rag1⎯/⎯ mice received either 2 x 107 wild-
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type splenocytes, 1.2 x 107 B cell-depleted splenocytes recovered from CD20 mAb-
treated mice, B cell-depleted splenocytes re-supplemented with 8 x 106 wild-type B 
lymphocytes or with 8 x 106 Ccl7⎯/⎯ B lymphocytes. In additional experiments, we 
generated a B cell-restricted Ccl7-deficient mouse model by reconstituting lethally-
irradiated wild-type animals with a mixture of μMT and Ccl7⎯/⎯ bone marrow as 
previously described 31,37. In this case, all reconstituted B cells originate from Ccl7⎯/⎯ 
bone marrow and are therefore completely deficient in Ccl7. The control group received a 
mixture of μMT and Ccl7+/+ bone marrow. Mice were allowed to recover for 5 weeks. 
Experiments were conducted according to the French veterinary guidelines and those 
formulated by the European Community for experimental animal use, and were approved 
by the Institut National de la Santé et de la Recherche Médicale. 
 
Echocardiographic measurements. Transthoracic echocardiography was performed 14 
days after surgery using an echocardiograph (ACUSON S3000™ ultrasound, Siemens 
AG, Erlangen Germany) equipped with a 14-MHz linear transducer (1415SP). The 
investigator was blinded to group assignment. Animals were anesthetized by isoflurane 
inhalation. Two-dimensional parasternal long-axis views of the left ventricle were 
obtained for guided M-mode measurements of the LV internal diameter at end diastole 
(LVDD) and end systole (LVDS), as well as the interventricular septal wall thickness, 
and posterior wall thickness at the same points. Percent fractional shortening (%FS) were 
calculated by the following formulas: %FS = [(LVDD - LVDS)/LVDD] X 100.  
 
Histopathological analysis.  Cardiac healing following myocardial infarction was 
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assessed at day 14. Hearts were excised, rinsed in PBS and frozen in liquid nitrogen. 
Hearts were cut by a cryostat (CM 3050S, Leica) into 7-μm-thick sections. Masson’s 
trichrome and Sirius Red stainings were performed for infarct size and myocardial 
fibrosis evaluation. Infarct size (in percent) was calculated as total infarct circumference 
divided by total LV circumference. The collagen volume fraction was calculated as the 
ratio of the total area of interstitial fibrosis to the myocyte area in the entire visual field of 
the section. B lymphocyte immunostaining was performed according to an indirect 
immunoperoxidase method using an anti-CD45R/B220 antibody (RA3-6B2, Southern 
Biotechnology) and AEC substrate kit (Dako). Endothelial cells forming capillaries were 
visualized after BS-1 lectin staining (FITC conjugated Griffonia simplicifolia, Sigma-
Aldrich) and arterioles using an anti-α-actin smooth muscle antibody (Abcam). 
 
Cells. Mice were killed at 12 h and on days 1, 3, 5, 7 and 14 after myocardial infarction 
(n = 5-10 mice per time point). Peripheral blood was drawn via inferior vena cava 
puncture with heparin solution. Whole blood was lysed after immunofluoresence staining 
using the BD FACS lysing solution and total blood leukocyte numbers were determined 
using Trypan Blue. Spleens were removed and bone marrow cells were drawn from 
femur and tibia and filtered through 40 μm nylon mesh (BD Biosciences). The cell 
suspension was centrifuged at 400 g for 10 min at 4 °C. Red blood cells were lysed 
(Sigma-Aldrich) and splenocytes and bone marrow cells were washed with PBS 
supplemented with 3% FBS. Infarct tissue and healthy hearts were harvested, minced 
with fine scissors, and placed into a cocktail of Collagenase I (450 U ml−1), Collagenase 
XI (125 U ml−1), DNase I (60 U ml−1), and Hyaluronidase (60 U ml−1) (sigma-Aldrich) 
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and shaken at 37 °C for 1 h. Cells were then triturated through nylon mesh (40 μm) and 
centrifuged (10 min, 400 g, 4 °C). Mononuclear cells were purified by density 
centrifugation (25 min, 400 g, room temperature). The resulting cell suspensions were 
washed and total leukocyte numbers were determined. 
 
Cell purification, culture and transmigration assay. B cells were isolated from 
C57BL/6J spleens using a B cell isolation kit (Miltenyi Biotec) according to the 
manufacturer’s protocol. B cells were stimulated during 48 h with 10 μg ml−1 of anti–
mouse IgM (Jackson ImmunoResearch Laboratories, Inc.) and 2.5 μg ml−1 of anti–mouse 
CD40 (clone HM40-3, BioLegend). Monocytes were isolated from bone marrow. Bone 
marrow fraction was enriched by neutrophils depletion using autoMACS columns 
(Miltenyi) and anti-Ly6G magnetic beads. 7/4hi monocytes (7/4 staining is equivalent to 
Ly6C staining 43) were then sorted on a FACSAria (BD Biosciences). In vitro monocytes 
transmigration was performed over cell culture inserts (Millicell-PCF, Millipore) with 
porous polycarbonate filters (8 μm pore size) in 24-well plates. Inserts were coated with 
rat-tail type I collagen (60 μg ml−1) for 30min at 37°C, then blocked with 3% BSA in 
PBS for 1 h at 37 °C. We used 300 μL of RPMI-FBS 10% containing 2 x 106 of B 
lymphocytes in the lower compartment and 200 μL containing 9 x 104 of 7/4hi monocytes 
were added to the upper compartment. Two μg ml−1 of Ccl7-specific neutralizing 
antibody or 1 μg ml−1 of Ccl2 neutralizing antibody (R&D systems) were added in the 
lower compartment before migration. Monocytes were allowed to migrate for 4 h at 37 
°C. The filters were then washed with PBS, and fixed in 1% paraformaldehyde. The 
upper surfaces of the filters were scraped with cotton swabs to remove the non-migrating 
Zouggari et al., NMED-A59989B-revision 
 32
cells. The filters were then stained with DAPI (Sigma-Aldrich). Migrating cells attached 
to the lower surfaces of the filters were visualized under an Axioimager Z1 microscope 
(Zeiss). Each experiment was performed in triplicate.  
 
Flow Cytometry. The following antibodies were used:  FITC-conjugated anti-CD11b 
(M1/70, BD Pharmingen), PE-conjugated anti-Ly6G (1A8, BD Pharmingen), PE-
conjugated anti-NK-1.1 (PK 136, BD Pharmingen), APC-conjugated anti-Ly-6B.2 (7/4, 
AbD Serotec), APC-conjugated anti-CD3e (17A2, eBioscience), FITC-conjugated anti-
CD4 (RM 4-5, eBioscience), PercP-conjugated anti-CD8a (53-6.7, BD Pharmingen), PE-
conjugated anti-CD45R/B220 (RA3-6B2, eBioscience), APC-conjugated anti-IgM (II/41, 
eBioscience), PE-Cy7-conjugated anti-CD11c (N418, eBioscience), APC-conjugated 
anti-CD19 (BD Pharmingen), V450-conjugated anti-IgD (BD Horizon), APC-conjugated 
anti-CD21 (BD Pharmingen), PE-conjugated anti-CD23 (BD Pharmingen), biotinylated 
anti-Ccl7 (PeproTech), and APC-conjugated anti-CD45.1 (A20, BD Pharmingen). 
Monocytes were identified as CD11bhi Ly6G⎯ 7/4hi/lo. Neutrophils were identified as 
CD11b+ Ly6Ghi 7/4hi. Macrophages/dendritic cells were identified as CD11chi.  NK cells 
were identified as CD11b+ Ly6G⎯ 7/4⎯ NK1.1+. Mature B lymphocytes were identified 
as B220hi IgMhi. Normalization to weight of infarct was performed for total cell numbers 
determination in the heart. Cells were analyzed using a flow cytometer (LSR II, BD).  
 
Antibody measurements. Circulating IgM, IgG1, and IgG2c levels were measured in 
plasma of treated mice at indicated time points using a chemiluminescent-based sandwich 
ELISA. 
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Quantitative real-time PCR. Quantitative real-time PCR was performed on a Step-one 
Plus (Applied Biosystems). GAPDH was used to normalize gene expression. The 
following primer sequence were used: forward 5’-CGT-
CCCGTAGACAAAATGGTGAA-3’, reverse 5’-
GCCGTGAGTGGAGTCATACTGGAA-CA-3’ ; IL1β : forward 5’-
GAAGAGCCCATCCTCTGTGA-3’, reverse 5’-GGGTGTGCCGTCTTTCATTA-3’; 
TNF-α : forward 5’-GATGGGGGGCTTCCAGAACT-3’, reverse 5’-
GATGGGGGGCTTCCAGAACT-3’ ; IL-18 : forward 5’-
AGTGAACCCCAGACCAGACTGA-3’, reverse 5’-




Chemokines levels. Plasma and/or heart levels of Ccl2, Ccl12, Cxcl13 and Ccl7 were 
measured using Quantikine Elisa Kits (R&D Systems and PeproThec, respectively) 
according to the manufacturer’s instructions. 
 
Population of patients with acute MI. The population and methods of the French 
registry of Acute ST-elevation and non–ST-elevation Myocardial Infarction (FAST-MI) 
have been described in detail in previous publications 44. Briefly, all patients ≥ 18 years 
of age were included in the registry if they had elevated serum markers of myocardial 
necrosis higher than twice the upper limit of normal for creatine kinase, creatine kinase-
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MB or elevated troponins, and either symptoms compatible with acute MI and/or 
electrocardiographic changes on at least two contiguous leads with pathologic Q waves 
(≥ 0·04 sec) and/or persisting ST elevation or depression > 0·1 mV. The time from 
symptom onset to intensive care unit admission had to be < 48 h. Patients were managed 
according to usual practice; treatment was not affected by participation in the registry. Of 
the 374 centers in France that treated patients with acute MI at that time, 223 (60%) 
participated in the registry. Among these, 100 centers recruited 1,029 patients who 
contributed to a serum bank. For the present study, 1,000 samples were available for 
CCL7 measurement and 959 samples were available for BAFF measurement. Written 
informed consent was provided by each patient. Their baseline characteristics were 
comparable to the overall population of the registry. More than 99% of patients were 
Caucasians. Follow-up was collected through contacts with the patients’ physicians, the 
patients themselves or their family, and registry offices of their birthplace. One-year 
follow-up was > 99% complete. The study was reviewed by the Committee for the 
Protection of Human Subjects in Biomedical Research of Saint Antoine University 
Hospital and the data file was declared to the Commission Nationale Informatique et 
Liberté. Human CCL7 analysis was carried out using the Bioplex Pro magnetic 
technology (Bio-Plex Pro™ Human Cytokine CCL7 Set #171-B6012M, Bio-Rad), 
following the manufacturer’s instructions. Frozen (−80 °C) EDTA plasma samples from 
each patient were all analyzed on the same day. Samples were thawed and spun at 2,500 
g for 15 min at room temperature prior to use and particle clear plasma was used at 1:4 
dilution. Data were acquired on 50 beads/patient and analyzed following a 1:4 serial 
dilution standard curve (concentration in range = 0.33-3472 pg ml−1) using the Bio-Plex 
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Manager 6.1 Software and 5PL logistic regression (FitProb. = 0.0000, ResVar. = 7.7585). 
Baff was measured using Quantikine Human Baff Immunoassay (ref SBLYS0, R&D 
Systems) following manufacturer’s instructions. The limit of detection was 3.38 pg ml−1. 
 
Statistical analysis. Results were expressed as mean ± SEM. Kruskal-Wallis was used to 
compare each parameter. Post hoc Mann–Whitney U tests with Bonferroni correction 
were then performed to identify which group differences accounted for the significant 
overall Kruskal-Wallis result. Statistical analysis in FAST-MI was conducted as follows. 
An outcome event was defined as all-cause death or non-fatal MI during the one-year 
follow-up period. The primary endpoint was defined as a composite of all-cause death 
and non-fatal MI, and was adjudicated by a committee whose members were unaware of 
patients’ medications, and blood measurements. Continuous variables are described as 
mean ± SD and categorical variables as frequencies and percentages. Baseline 
demographic and clinical characteristics, treatment factors, and therapeutic management 
during hospitalisation were compared among patients with or without detectable 
circulating CCL7 levels using chi-square or Fisher’ s exact tests for discrete variables, 
and by unpaired T tests, Wilcoxon sign-rank tests for continuous variables. Survival 
curves according to detectable or undetectable CCL7 levels are estimated using the 
Kaplan Meier estimator. We used a multivariable Cox proportional-hazards model to 
assess the independent prognostic value of variables with the primary endpoint during the 
1-year follow-up period. The multivariable model comprised sex, age, previous or current 
smoking, family history of coronary disease, history of hypertension, previous MI, heart 
failure, renal failure, diabetes, heart rate at admission, Killip class, left ventricular 
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ejection fraction, hospital management (including reperfusion therapy, statins, beta-
blockers, clopidogrel, diuretics, digitalis, heparin), troponin I and log CRP levels. Results 
are expressed as hazard ratios for Cox models with 95% confidence intervals (CIs). All 
statistical tests were two-sided and performed using SAS software version 9.1. 
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